Prion Paradigm: Understanding Neurodegenerative Disorders

Apply

Prion Paradigm: Understanding Neurodegenerative Disorders

Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2019, Vol 13, Issue 5

Abstract

The concept of a protein that could work as an “infecting particle” was a revolutionary idea in Biology and Medicine and, as other paradigms when they arise, took time to be accepted by the scientific community . The international economic impact of Bovine Spongiform Encephalopathy and its linkage to a human epidemy, crossing the barrier among mammal species, drove special attention to the prion hypothesis. The “variant of Creutzfeldt Jakob Disease” (vCJD) characterized this new and mortal epidemy. In those circumstances, in 1997 Stanley B. Prusiner received the Nobel Prize for all his work that culminated with the proposition of the “prion”, a name that he gave to the “infecting protein”. Creutzfeldt Jakob Disease (CJD) was first attributed to a kind of “slow virus”, a concept introduced by Sigurdsson in 1954 to some pathologic conditions with long latency period, also with progressive and fatal clinical feature [1]. The demonstration of the existence of that slow virus was pursued by several researchers, but without conclusive result . After his own experience, when he did medical residence, caring for a CJD patient, Prusiner started to study and research about the etiology of CJD. Opened to new findings that he was discovering, he needed to perseverate and struggle for his new ways to understand a revolutionary explanation for that etiopathogenic mechanism. Could be, the replication of a protein like a virus, a daring idea against a “biologic dogma”? The occurrence of the vCJD and the strong association with BSE confirmed the prion hypothesis consecrated by the Nobel Prize to Prusiner and a new scientific paradigm was established. So, the idea of contagion and infectious diseases were amplified beyond germs. After that, the continuing research about the prion mechanism in other diseases opened for the discovery of different forms of prion protein and its equivalent clinical manifestations. Under these conditions, we have now etiologic correlation of each specific protein complex to each neurodegenerative disease [2-4]. Even some other conditions have this hypothesis as, for example, type 2 diabetes. The transformation of a normal protein in a pathologic one can occur by genetic factors, sporadic mutation, or transmission . We need to think and teach more frequently that such diseases have a prion etiopathogenic mechanism, as Parkinson, or Huntington disease, for example. We have to engage in the new paradigm. One special aspect of all those conditions is Alzheimer disease. With the aging of the population, some degenerative disorders, as that one, became more frequent. In the United States, patients with Alzheimer, more than 65 years old, until the year 2050, are going from 5.2 million to 14 million. Each year, 500.000 new cases are expected. 200 billion dollars are spent annually to care for those condition in USA, including the caretakers. About the treatment of Alzheimer, from 2002 to 2012, 413 clinical assays were performed with a tax of failure of 99,6%. The only success approved by the FDA was memantine and MDMA, that provide symptomatic treatment to moderate and severe cases.

Authors and Affiliations

Afonso Carlos Neves

Keywords

Afonso Carlos Neves Neurodegenerative; Protein; Bovine; Encephalopathy; Creutzfeldt Jakob Disease; Slow Virus; Biomedical Articles; BJSTR Open Access Journals; Pharmacy; Cancer

EP ID EP585648
DOI 10.26717/BJSTR.2019.13.002464
Views 151
Downloads 0